JPH0586956B2 - - Google Patents

Info

Publication number: JPH0586956B2
Authority: JP; Japan
Prior art keywords: thiazolo; groups; group; compound; pyrimidin
Prior art date: 1986-12-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP61314665A

Other languages

English (en)

Japanese (ja)

Other versions

JPS63166887A (ja

Inventor

Masayoshi Tsuji

Toshitaka Inoe

Yoshihiro Tagami

Masaru Saida

Yasuaki Taniguchi

Masahiro Nakahara

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hisamitsu Pharmaceutical Co Inc

Original Assignee

Hisamitsu Pharmaceutical Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-12-27

Filing date

1986-12-27

Publication date

1993-12-14

1986-12-27 Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc

1986-12-27 Priority to JP61314665A priority Critical patent/JPS63166887A/ja

1988-07-11 Publication of JPS63166887A publication Critical patent/JPS63166887A/ja

1993-12-14 Publication of JPH0586956B2 publication Critical patent/JPH0586956B2/ja

Status Granted legal-status Critical Current

Links

CDUYCVWBLGEWSY-UHFFFAOYSA-N 5h-[1,3]thiazolo[3,2-a]pyrimidine Chemical class C1C=CN=C2SC=CN12 CDUYCVWBLGEWSY-UHFFFAOYSA-N 0.000 claims description 10
125000003277 amino group Chemical group 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 4
125000002947 alkylene group Chemical group 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
125000004434 sulfur atom Chemical group 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
150000001875 compounds Chemical class 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
-1 methylamino, ethylamino, propylamino, butylamino, isobutylamino, pentylamino, isopentylamino Chemical group 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
238000000921 elemental analysis Methods 0.000 description 10
238000002844 melting Methods 0.000 description 10
230000008018 melting Effects 0.000 description 10
230000000694 effects Effects 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000000202 analgesic effect Effects 0.000 description 7
239000013078 crystal Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000000730 antalgic agent Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000000034 method Methods 0.000 description 5
229940035676 analgesics Drugs 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
241000700159 Rattus Species 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000000679 carrageenan Substances 0.000 description 3
229940113118 carrageenan Drugs 0.000 description 3
235000010418 carrageenan Nutrition 0.000 description 3
229920001525 carrageenan Polymers 0.000 description 3
238000001816 cooling Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
238000010992 reflux Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
238000005303 weighing Methods 0.000 description 3
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
208000018522 Gastrointestinal disease Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
206010030124 Oedema peripheral Diseases 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
125000003282 alkyl amino group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000006698 induction Effects 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
239000000203 mixture Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000008096 xylene Substances 0.000 description 2
UUHXCOGOBLTVJX-UHFFFAOYSA-N 1-cyclohexyl-2-phenylhydrazine Chemical group C1CCCCC1NNC1=CC=CC=C1 UUHXCOGOBLTVJX-UHFFFAOYSA-N 0.000 description 1
RGXUNBIQSDFKSO-UHFFFAOYSA-N 2,3-dihydro-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical class O=C1C=CN=C2SCCN12 RGXUNBIQSDFKSO-UHFFFAOYSA-N 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
REGFWZVTTFGQOJ-UHFFFAOYSA-N 4,5-dihydro-1,3-thiazol-2-amine Chemical compound NC1=NCCS1 REGFWZVTTFGQOJ-UHFFFAOYSA-N 0.000 description 1
XVTANWUGQJTFBY-UHFFFAOYSA-N 7-methyl-2,3-dihydro-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound CC1=CC(=O)N2CCSC2=N1 XVTANWUGQJTFBY-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical group S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 1
YENBJQJVQRQIKV-UHFFFAOYSA-N OO.CCO Chemical compound OO.CCO YENBJQJVQRQIKV-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000008896 Opium Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
UEZROEGYRDHMRV-UHFFFAOYSA-N [1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical class O=C1C=CN=C2SC=CN12 UEZROEGYRDHMRV-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000008687 biosynthesis inhibition Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
BPHHNXJPFPEJOF-UHFFFAOYSA-J chembl296966 Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C(N)C2=C(O)C(N=NC3=CC=C(C=C3OC)C=3C=C(C(=CC=3)N=NC=3C(=C4C(N)=C(C=C(C4=CC=3)S([O-])(=O)=O)S([O-])(=O)=O)O)OC)=CC=C21 BPHHNXJPFPEJOF-UHFFFAOYSA-J 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
CVEFXRBXZIGLMA-UHFFFAOYSA-N ethyl 4-[(2-methylpropan-2-yl)oxy]-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)COC(C)(C)C CVEFXRBXZIGLMA-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
238000011835 investigation Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
239000011707 mineral Substances 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960001027 opium Drugs 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP61314665A 1986-12-27 1986-12-27 新規なチアゾロ〔３，２−ａ〕ピリミジン誘導体 Granted JPS63166887A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP61314665A JPS63166887A (ja)	1986-12-27	1986-12-27	新規なチアゾロ〔３，２−ａ〕ピリミジン誘導体

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP61314665A JPS63166887A (ja)	1986-12-27	1986-12-27	新規なチアゾロ〔３，２−ａ〕ピリミジン誘導体

Publications (2)

Publication Number	Publication Date
JPS63166887A JPS63166887A (ja)	1988-07-11
JPH0586956B2 true JPH0586956B2 (zh)	1993-12-14

Family

ID=18056066

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP61314665A Granted JPS63166887A (ja)	1986-12-27	1986-12-27	新規なチアゾロ〔３，２−ａ〕ピリミジン誘導体

Country Status (1)

Country	Link
JP (1)	JPS63166887A (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8119647B2 (en) *	2008-04-23	2012-02-21	Glenmark Pharmaceuticals S.A.	Fused pyrimidineone compounds as TRPV3 modulators

1986
- 1986-12-27 JP JP61314665A patent/JPS63166887A/ja active Granted

Also Published As

Publication number	Publication date
JPS63166887A (ja)	1988-07-11

Publication	Publication Date	Title
US5985894A (en)	1999-11-16	N-substituted quinolines
JPS623153B2 (zh)	1987-01-23
FI76809B (fi)	1988-08-31	Foerfarande foer framstaellning av terapeutiskt anvaendbara nya 5-(3-pyridyl)pyrrolo/1,2-c/tiazol-7- karboxamid-derivat.
CA1294276C (en)	1992-01-14	Benzothiazine dioxide derivatives
JPS62263177A (ja)	1987-11-16	ベンズイミダゾ−ル化合物
JPH0374230B2 (zh)	1991-11-26
JPH0586956B2 (zh)	1993-12-14
EP0349902A2 (en)	1990-01-10	Processes for the preparation of morniflumate and analogous compounds
JPS5914037B2 (ja)	1984-04-02	イソキノリン誘導体、その製造方法およびそれを含有する医薬組成物
US4461768A (en)	1984-07-24	Anti-inflammatory 1,2-benzothiazines
EP0085866B1 (en)	1986-04-09	Derivatives of benzo-1,2-thiazine-1,1-dioxide, a process for their preparation and pharmaceutical compositions containing the same
JPS6241234B2 (zh)	1987-09-02
US4680405A (en)	1987-07-14	Process for preparing 2-[(N-2-pyridylcarbomyl)methyl]saccharin
JPH0529035B2 (zh)	1993-04-28
JPH0710863B2 (ja)	1995-02-08	エーテル化若しくはエステル化しうるジヒドロキシ基により位置２で置換された４―ｏｈキノリンカルボン酸の新規の誘導体、その製造方法、及び医薬としてのその使用
JPS63301873A (ja)	1988-12-08	２−アルキルスルフイニル−４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍薬
CA1122601A (en)	1982-04-27	4-(2'-pyridylamino)phenylacetic acid derivatives
JPS5810387B2 (ja)	1983-02-25	４，５，６，７テトラヒドロイミダゾ〔４，５−ｃ〕ピリジン誘導体及びその製法
JP2649168B2 (ja)	1997-09-03	新規な５，６−ジフェニル−１，２−ジヒドロ−３Ｈ−ピロロ［１，２−ａ］ピロール−１−カルボン酸誘導体
US4895956A (en)	1990-01-23	3-aroyl-6,7-dihydro-5H-pyrrolo(1,2-c)imidazole-7-carboxylic acid derivatives
KR820000495B1 (ko)	1982-04-08	퀴나졸린 유도체의 제조방법
JPH0633284B2 (ja)	1994-05-02	新規な三環系化合物
JPS60208971A (ja)	1985-10-21	新規なオキサゾ−ル誘導体
KR820000492B1 (ko)	1982-04-08	퀴나졸린 유도체의 제조방법
PL149608B1 (en)	1990-02-28	A method of obtaining new derivatives of benzothiazine dioxide